1H-1,2,4-triazol-3-yl-anilines: Novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2

Chemical Biology and Drug Design

Volumn 69, Issue 5, 2007, Pages 331-337

  Kiselyov, Alexander S ^a   Piatnitski, Evgueni ^b   Milligan, Daniel ^b   Ouyang, Xiaohu ^b  

^a CHEMDIV INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

1, 2, 4 triazol 3 yl anilines; Angiogenesis; ATP competitive kinase inhibitors; Vascular endothelial growth factor receptor 2

Indexed keywords

1H 1,2,4 TRIAZOL 3 YL ANILINE; 2 (1 (3 BROMOPHENYL) 1H 1,2,4 TRIAZOL 3 YL) N (PYRIDIN 4 YL METHYL)ANILINE; 2 (1 (3 BROMOPHENYL) 1H 1,2,4 TRIAZOL 3 YL) N (QUINOLIN 4 YLMETHYL)ANILINE; 2 (1 (3 TERT BUTYLPHENYL) 1H 1,2,4 TRIAZOL 3 YL) N (PYRIDIN 4 YL METHY)ANILINE; 2 (1 (4 METHYL 3 (TRIFLUOROMETHYL)PHENYL) 1H 1,2,4 TRIAZOL 3 YL) N (PYRIDIN 4 YL METHYL)ANILINE; ANILINE DERIVATIVE; N (PYRIDIN 4 YL METHYL) 2 (1 (3 (TRIFLUOROMETHOXY)PHENYL) 1H 1,2,4 TRIAZOL 3 YL)ANILINE; N (PYRIDIN 4 YL METHYL) 2 (1 (3 (TRIFLUOROMETHYL)PHENYL) 1H 1,2,4 TRIAZOL 3 YL)ANILINE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; ENZYMATIC ASSAY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MOLECULE; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; CELLS, CULTURED; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIAZOLES;

EID: 34249311318     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00507.x     Document Type: Article

References (25)

1. Risau W. (1997) Mechanism of angiogenesis. Nature 386 : 671 674.
2. Klagsbrun M., Moses M.A. (1999) Molecular angiogenesis. Chem Biol 6 : R217 R224.
3. Hanahan D., Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 : 353 364.
4. Eskens F. (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going Br J Cancer 90 : 1 7.
5. Olsson A.-K., Dimberg A., Kreuger J., Claesson-Welsh L. (2006) VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 5 : 359 371.
6. Zachary I. (2003) VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31 : 1171 1177.
7. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 : 391 400.
8. Saaristo A., Karpanen T., Alitalo K. (2000) Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19 : 6122 99.
9. Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 : 27 31.
10. Fuh G., Li B., Crowley C., Cunningham B.C., Wells J.A. (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273 : 11197 11204.
11. Barleon B., Totzke F., Herzog C., Blanke S., Kremmer E., Siemeister G., Marme D., Martiny-Baron G. (1997) Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272 : 10382 10388.
12. Kiselyov A.S., Balakin K., Tkachenko S.E. (2007) VEGF/VEGFR signaling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 16 : 83 107.
13. Ciardiello F., Caputo R., Damiano V., Caputo R., Troiani T., Vitagliano D., Carlomagno F., Veneziani B.M., Fontanini G., Bianco A.R., Tortora G. (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9 : 1546 56.
14. Drevs J., Konerding M.A., Wolloscheck T., Wedge S.R., Ryan A.J., Ogilvie D.J., Esser N. (2005) The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affect microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7 : 347 354.
15. Hess-Stumpp H., Haberey M., Thierauch K.H. (2005) PTK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 787/ZK 6:550 557.
16. Manley P.W., Furet P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell C.R., Wood J. (2002) Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem 45 : 5687 5693.
17. Piatnitski E.L., Duncton M.A.J., Kiselyov A.S., Katoch-Rouse R., Sherman D., Milligan D.L., Balagtas C., Wong W.C., Kawakami J., Doody J.F. (2005) Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett 15 : 4696 4698.
18. Duncton M.A.J., Piatnitski E.L., Katoch-Rouse R., Smith L.M., Kiselyov A.S., Milligan D.L., Balagtas C., Wong W.C., Kawakami J., Doody J.F. (2006) Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett 16 : 1579 1581.
19. Kiselyov A.S., Semenova M., Semenov V.V., Piatnitski E.L. (2006) 1-(Azolyl)-4-(aryl)- phthalazines: novel potent inhibitors of VEGF receptors I and II. Chem Biol Drug Des 68 : 250 256.
20. Kiselyov A.S., Semenov V.V., Milligan D. (2006) 4-(Azolylphenyl)- phthalazin-1-amines: novel inhibitors of VEGF receptors I and II'. Chem Biol Drug Des 68 : 308 314.
21. Kiselyov A.S., Piatnitski L.E., Samet A.V., Kisly V.P., Semenov V.V. (2007) Ortho- Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. Bioorg Med Chem Lett 17 : 1369 1375 and references cited therein.
22. Bowie R.A., Thomason D.A. (1972) Ring transformations involving chloroheterocycles. Part III. Reaction of 4-chloroquinazolines with hydrazines. J Chem Soc [Perkin 1] 1842 1848.
23. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., Appelt K. (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7 : 319 324.
24. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res 28 : 235 242.
25. Jain R.K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 : 58 62.